Core Viewpoint - The oral semaglutide (Wegovy pill) has gained FDA approval, marking a significant turning point for Novo Nordisk A/S [1] Group 1: FDA Approval Impact - The approval of the oral semaglutide is seen as a pivotal moment for Novo Nordisk, potentially enhancing its market position [1] Group 2: Company Background - Novo Nordisk is recognized for its innovative approaches in the pharmaceutical industry, particularly in diabetes and obesity treatments [1]

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Dec. 23, 2025. You can follow the latest updates on the market here in our daily live blog. Update: 4:04 p.m ET Closing Bell The U.S. markets are now closed. America might be lacking in consumer confidence, but its traders are not. Before a shortened trading day tomorrow and a market closu ...

Welcome to Morning Brief presented by Robin Hood, the home to commission free trading. I'm Yahoo Finance executive [music] editor Brian Sazi. Let's fire up three things I think you need to know today.First up, if you're feeling the holiday sleepies, I say it's time to wake up because we are witnessing a market [music] in rally mode into uh the new year, just not happening now. More on that in a second. I'm [music] really locked in on the tech names like Nvidia, which has quietly tacked on a 5% gain the past ...

U.S. stock markets opened with a cautious tone this Tuesday, December 23rd, 2025, as investors digested a surprisingly strong third-quarter GDP report and looked ahead to further economic data in a holiday-shortened trading week. While Monday saw broad gains across major indexes, today's opening session reflected a more subdued sentiment, with the Dow Jones Industrial Average (DJIA) showing a slight dip, while the S&P 500 (SPX) and Nasdaq Composite (IXIC) edged fractionally higher.Major Index Performance at ...

Market Performance - U.S. stocks showed mixed trading, with the Nasdaq Composite gaining approximately 0.2% on Tuesday [1] - The Dow decreased by 0.01% to 48,357.98, while the S&P 500 rose by 0.15% to 6,888.53 [1] Sector Performance - Communication services sector increased by 0.9% on Tuesday [1] - Consumer staples stocks fell by 0.4% [1] Economic Indicators - U.S. GDP grew an annualized 4.3% in the third quarter, the highest growth in two years, up from 3.8% in the previous quarter, and surpassing market expectations of 3.3% [2][10] - U.S. durable goods orders declined by 2.2% month-over-month to $307.4 billion in October, following a revised growth of 0.7% in September [11] Commodity Prices - Oil prices decreased by 0.3% to $57.81, while gold prices increased by 0.3% to $4,480.60 [5] - Silver rose by 1.3% to $69.485, and copper increased by 0.5% to $5.5365 [5] Global Market Overview - European shares were mixed, with the eurozone's STOXX 600 gaining 0.4% and Spain's IBEX 35 Index falling by 0.1% [6] - Asian markets closed mixed, with Japan's Nikkei 225 gaining 0.02% and Hong Kong's Hang Seng falling by 0.11% [7] Company Stock Movements - PicoCELA Inc. shares surged 144% to $0.3045 [9] - Highway Holdings Ltd shares increased by 78% to $1.48 after a nonbinding letter of intent for acquisition [9] - Trinity Biotech PLC shares rose by 62% to $1.45 following an order for HIV tests [9] - Reviva Pharmaceuticals Holdings Inc shares dropped 51% to $0.29 after a regulatory update [9] - Starfighters Space Inc shares fell 41% to $18.42 after a significant rally [9] - Haoxin Holdings Ltd shares decreased by 42% to $0.75 after a prior surge [9]

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]

Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).The update is regarding brilaroxazine, a novel serotonin-dopamine and neuroinflammatory signaling modulator, in late-stage development for schizophrenia.In written feedback, the FDA recommended a second Phase 3 clinical trial for brilaroxazine in patients with schizophrenia to, among other things, generate addition ...

Core Insights - Companies with a long history of dividend increases are likely candidates for future dividend raises, indicating stability and reliability in their financial performance [1]. Company Summaries - **Procter & Gamble**: The company has raised its dividend for 69 years, with a recent revenue increase of 2% to $84.3 billion and operating cash flow of $17.8 billion. Its forward yield is approximately 3% [2]. - **Johnson & Johnson**: This company has increased its dividend for 63 consecutive years, recently raising it by 4.8%. In the last quarter, revenue rose 7% to $24 billion, and per-share earnings surged 91% to $2.12. The company also raised its 2025 sales outlook [3]. - **Altria**: Altria has increased its dividend to $1.06 from $1.02, marking the 60th increase in 56 years. From 2020 to 2024, it has paid out $32 billion in dividends and conducted $7.8 billion in stock buybacks. Altria is known for its Marlboro brand [4]. - **Coca-Cola**: The company announced its 63rd consecutive annual dividend increase, raising the quarterly dividend by approximately 5.2% from 48.5 cents to 51 cents per share. Coca-Cola reported revenue of $12.5 billion, up 5%, with earnings rising 30% to $0.86 per share [5].

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITPApproval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptomsITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, December 23, 2025 – The European Commission ...